This is legitimately terrible for OpenAI --- but also Anthropic --- and it relates to their work in drug discovery.
I read this as: prompts will be monitored and potentially acted on if we think there’s something scientifically and/or commercially valuable being disclosed.
Now, the big problem for Anthropic is that they are increasingly seen to be competing with their customers. Outside of SF, many people also think of OpenAI/ChatGPT and Anthropic/Claude as somewhat interchangeable companies and products --- aka, if OpenAI do something, surely Anthropic will do it too?
As so much IP relates to drug targets and people disclose these to Claude, I think we will see a lot of pharma companies stop using these tools or put up a lot of internal guardrails.
Quote
Thomas Wolf
@Thom_Wolf
wtf is this way to handle mathematicians work and scientific communication
TLDR: Leven and Tristan worked over several months on one of the Millenium Prize Problems with various AIs to reach final interesting results. OpenAI apparently heard about it in the last days and x.com/deaneyang/stat…